Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.48 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 8/20 | 0.40 |
| ▸ | NPC1 | O15118 | 5/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | PTBP1 | P26599 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23008684 | 0.84 | ALDH1A1 (0.42) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL27611283 | 0.82 | CES2 (0.45) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL26614826 | 0.82 | ALDH1A1 (0.43) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL3257574 | 0.79 | RAB9A (0.54) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL13186864 | 0.79 | ALDH1A1 (0.44) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL22701274 | 0.79 | KDM4E (0.46) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL8834627 | 0.79 | ALDH1A1 (0.41) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL26707241 | 0.78 | KMT2A (0.49) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL19068888 | 0.78 | CES2 (0.41) | ALDH1A1CES2CES1KDM4ELMNA | |
| SCHEMBL20653343 | 0.77 | MAPK1 (0.42) | ALDH1A1CES2CES1KDM4ELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | Commissariat à l'Energie Atomique et aux Energies Alternatives (FR) | 2020-11-12 | — | — | US | disclosed |
| US-20180212166-A1 | COMPOSITION COMPRISING ORGANIC SEMICONDUCTING COMPOUNDS | MERCK PATENT GMBH (DE) | 2018-07-26 | — | — | US | disclosed |
| EP-2818462-B1 | CYCLIC AZINE DERIVATIVES, PROCESSES FOR PRODUCING THESE, AND ORGANIC ELECTROLUMISCENT ELEMENT CONTAINING THESE AS COMPONENT | TOSOH CORP (JP) | 2017-11-08 | — | — | EP | disclosed |
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | GRACEL DISPLAY INC. (KR) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100045170-A1 | Novel organic electroluminescent compounds and organic electroluminescent device using the same | OCIAD1, OCIAD2, ORMDL3 | ALDH1A1 101/4885CES2 1341/4885CES1 955/4885 |
| US-20200354364-A1 | PURINE DERIVATIVES FOR USE AS MEDICAMENT AND FOR USE IN TREATING NEURODEGENERATIVE OR NEURO-INFLAMMATORY DISORDERS | TPMT, ADORA2A, PNP | ALDH1A1 514/4885CES2 1866/4885CES1 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.